<DOC>
	<DOCNO>NCT02673437</DOCNO>
	<brief_summary>Rivaroxaban medicine reduces formation blood clot . Acute coronary syndrome ( ACS ) comprise range disorder , include heart attack unstable angina , cause sudden reduction blood flow part heart muscle . This study aim collect information use rivaroxaban safety use patient prevention atherothrombotic ( plaque rupture lead blood clot ) event follow ACS , first three month start . This study request European regulatory body ( EMA ) responsible use safety medicine . It last approximately 3 year national study cover whole England Wales . The study aim recruit 1193 patient prescribed rivaroxaban antiplatelet therapy 1193 patient prescribed alternative dual antiplatelet therapy secondary prevention atherothrombotic event follow ACS . Each patient monitor first 13 week hospital admission ACS . Patients choose take part complete consent form . The patient 's care team ask complete baseline questionnaire patient time medicine give questionnaire 16 week later , specifically ask patient 's experience whilst medication . If anything unusual report observation period , care team may ask fill followup questionnaire . With patient 's consent , study team also inform patient 's General Practitioner ( GP ) participation study ask GP complete abridge questionnaire patient 's medical record . The study team analyse aggregate data , carefully protect patient confidentiality , classify adverse event interest , particular bleeding event .</brief_summary>
	<brief_title>Rivaroxaban ACS Specialist Cohort Event Monitoring Study</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Age 18 year Patients newly prescribe rivaroxaban combination standard oral antiplatelet therapy current standard antiplatelet combination therapy ( least dual therapy , monotherapy ) secondary prevention patient ACS Patients prescribed dual antiplatelet therapy secondary prevention ACS Patients provide sign , informed consent Patients newly prescribe rivaroxaban : elective major hip knee replacement ; prevention stroke systemic embolism nonvalvular atrial fibrillation ( AF ) ; treatment deep vein thrombosis ( DVT ) pulmonary embolism ( PE ) prevention recurrent DVT PE follow acute DVT Patients commence rivaroxaban date market launch indication secondary prevention ACS study start ( tbc anticipate Q1 2015 ) Patients past use rivaroxaban factor Xa inhibitor direct thrombin inhibitor record prior study start previous six month , indication Patients past use rivaroxaban record prior study start indication secondary prevention patient ACS Patients receive factor Xa inhibitor direct thrombin inhibitor management ACS contextual cohort Patients dual antiplatelet therapy record immediately prior ACS</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Acute coronary syndrome</keyword>
</DOC>